ANTABIO - Key Persons
Biography
Benedikt was formerly CEO of Genticel and has over 25 years of experience in Life Science industry. He was the founder of BT Pharma in 2001, which became Genticel in 2010 and raised over 34 M in venture funding. In 2014 he took the company public on Euronext in Paris and Brussels and hereby raised another 34.7 M . In February 2017 he merged Genticel into Genkyotex (GKTX). Previously, Benedikt held senior R & D and licensing positions at NOVARTIS (1996 - 2000) and SANDOZ (1991 - 1996). Since 2018 he provides biotech management consulting services and is Venture Partner at IRDI SORIDEC GESTION, a French Capital Investment firm with nearly 300 M under management. Benedikt holds a PhD degree from the University of Ghent, Belgium and an MBA from INSEAD, France.
Biography
Christophe Ricard obtained a MBA in Switzerland and USA and after fifteen years in the pharmaceutical industry, where he worked in various positions in Europe and in Latin America, he became President and CEO of OM Pharma in Geneva, a position he held from 1995 till 2009. In 2009 Christophe moved to London, whilst maintaining close links in Geneva, and dedicates his time to his new activities in several countries. In 2010 he created the NGO Pan-Soy in Peru, in 2011 he took control of GreenGT, a Swiss company specialized in the supply of electric hydrogen solutions of strong power, and in 2012 he set up a hotel business called Serout Jenna in Marrakech, as well as a real estate company Caoba in Lima. Finally, with the cooperation of his children, he createdThe Ricard Foundation in London in 2015, to finance socially responsible charitable projects.
Biography
Before joining Turenne Capital as Investment Director Healthcare in July 2022, Claire worked for 7 years in the Omnes Capital VC Healthcare team. She began her career in research at the Singapore Institute for Neurotechnology. Claire Poulard holds a master's degree in Pharmaceutical Management and Biotechnology from ESCP Europe and a master in Bioengineering and Neuroscience Innovation from ESPCI (Ecole Supérieure de Physique et Chimie Industrielle).
Biography
Geoff has extensive experience in new medicine discovery across many therapeutic areas and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was the founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Geoff provides scientific and strategic evaluation and advice as an independent consultant to a wide range of drug discovery organisations. Clients include large and small biopharma companies, CROs, VCs, academic groups and medical research charities. He is a founder of INMedD, a new medicines discovery social enterprise.
Biography
Gordon has over 25 years' experience in high tech, med tech and biotech. During his career, he has raised over M175 in venture capital funding, over M50 in an IPO and has been involved in 10 M&A / Exit transactions. Gordon is the Former Vice President and Chief Financial Officer of Novexel, an antibacterial drug discovery company. At Novexel, he participated in a preclinical license negotiation which brought the company a M75 upfront payment in 2008 and negotiated the sale of Novexel to Astra Zeneca for cash consideration of approximately 500 million in 2009.
Job Titles:
- Co - Founder
- Member of the Board
Helmuth a co-founder of Antabio, was part of the founding team of Galapagos, now a clinical stage development company, in 1998. As Head of Science, he established multimillion dollar alliances with GSK, Incyte, Pharmacia, CF foundation and others. Since Galapagos Helmuth founded BioConsilium and co-founded drug-discovery companies Audion Therapeutics (2008 based on Harvard IP) targeting hearing loss, Eli Lilly and INKEF Capital are current investors; Effecta Pharma focussing on novel antivirals (2009) (in particular flavivirus); Citryll a single asset company focussing on a first in class NET inhibiting therapeutic antibody targeting SLE, vasculitis, RA and other autoimmune diseases.
Job Titles:
- Member of the Board
- Senior Advisor Global Development at Institut Pasteur
Jean-Loup is a Senior Advisor Global Development at Institut Pasteur, promoting from New York the Institut Pasteur Global Health Genomics Initiative. He is the Founder and former CEO of IDM Pharma Inc. (formerly NASDAQ: IDMI, now part of Takeda Oncology) a developer of anti-cancer immunotherapy drugs and vaccines and a pioneer of Cancer Cellular immunotherapy. Jean-Loup got his academic training as senior scientist at the Cancer Biology Department at Harvard School of Public Health, Boston, and is a former associate professor in cellular biology at the Medical School of Tours University, France.
Job Titles:
- Chief Executive Officer
- Founding CEO
Biography
Marc, founding CEO of Antabio, is a molecular and cellular microbiologist with over 25 years' experience in academia and biotech. Prior to founding Antabio, Marc held different research positions at various institutions globally such as CNRS and Inserm (France), CSIC (Spain) and Emory University (USA), authoring over 20 peer-reviewed articles in the field of bacterial pathogenesis and antibiotic resistance. Under Marc's leadership, Antabio has raised 44m funding and received numerous awards including CARB-X and Wellcome Trust (twice). Marc is a member of the Board of the BEAM Alliance (European Alliance of Biopharmaceutical companies combating Anti-Microbial resistance), and a member of the SAB of JPIAMR (the Joint Programming Initiative on Antimicrobial Resistance).
Biography
Nitza founded her consulting company, NtzConsulting, in 2018. She represents Omnes Capital at Antabio's board of directors. Nitza is the co-founder of Gensight Biologics (Gene therapy for ophthalmologic diseases) and BrainEver (Advanced medicinal products to treat neurodegenerative diseases). After a post doc at Northwestern & Rush University (Chicago, USA), she joined the pharma industry to develop medicines for neurologic and psychiatric disorders at Servier. Then she moved to the biotech world, joining Fovea Pharma in 2009, that became Ophthalmology Division of Sanofi. She contributed to the start of Tissium, while co-founding GenSight Biologics, then BrainEver. Her salient skill remains the translation of transformative technology/science into human innovative therapeutics addressing unmet medical needs.
Biography
During his early career, Pierre Arnaud was an engineer in the automotive industry before switching to M&A activities. He joined Galia Gestion in 2015 where he realized several operations from venture to LBO, and now acts as a Board member of about 10 companies based in the South West of France, including Fineheart, a Med Tech Device company based in Bordeaux. Galia Gestion is a regional private equity fund investing between 0.5 to 4 M in venture capital, growth capital and LBO.